SCHEMBL20838424

SCHEMBL20838424

O=C1c2ccccc2C(=O)N1CC(O)C(c1ccc(F)cc1)c1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46
GMNN O75496 1/20 0.46
LMNA P02545 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CASP3 P42574 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29881198 1.00 MEN1 (0.46) MEN1KMT2ATSHRCYP1A2CYP3A4
SCHEMBL20838423 1.00 MEN1 (0.46) MEN1KMT2ATSHRCYP1A2CYP3A4
SCHEMBL29881121 0.92 MEN1 (0.45) MEN1KMT2ATSHRCYP1A2CYP3A4
SCHEMBL20838364 0.92 MEN1 (0.45) MEN1KMT2ATSHRCYP1A2CYP3A4
SCHEMBL20838366 0.92 MEN1 (0.45) MEN1KMT2ATSHRCYP1A2CYP3A4
SCHEMBL19329828 0.90 CASP3 (0.49) MEN1KMT2ATSHRCASP3RAB9A
SCHEMBL20838442 0.90 CASP3 (0.49) MEN1KMT2ATSHRCASP3RAB9A
SCHEMBL20838349 0.88 ALDH1A1 (0.48) KMT2ATSHRMAPTCASP3RAB9A
SCHEMBL19329978 0.88 ALDH1A1 (0.48) KMT2ATSHRMAPTCASP3RAB9A
SCHEMBL22723198 0.83 MAPT (0.44) KMT2ATSHRCYP3A4CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426656-B1 TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2021-05-12 EP disclosed
US-10858366-B2 Tricyclic compounds useful to treat orthomyxovirus infections NOVARTIS AG (CH) 2020-12-08 US disclosed
US-20190092780-A1 TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2019-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858366-B2 Tricyclic compounds useful to treat orthomyxovirus infections ZC3HAV1, OTC, THOP1 MEN1 2573/4885KMT2A 3502/4885TSHR 3950/4885
US-20190092780-A1 TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS ZC3HAV1, OTC, THOP1 MEN1 2573/4885KMT2A 3502/4885TSHR 3950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.